View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 1, 2019

Achillion doses first subject in Phase I trial of ACH-5228

Achillion Pharmaceuticals has dosed the first subject in a Phase I multiple ascending dose (MAD) trial to investigate ACH-5228 for the treatment of complement-mediated diseases.

Achillion Pharmaceuticals has dosed the first subject in a Phase I multiple ascending dose (MAD) trial to investigate ACH-5228 for the treatment of complement-mediated diseases.

ACH-5228 is a new oral small-molecule inhibitor of factor D.

Achillion is expected to enroll around 38 subjects outside the US as part of the randomised, placebo-controlled, MAD trial. Patients will be distributed into four separate cohorts.

The trial’s primary objective is an assessment of safety and tolerability. Its secondary objectives comprise evaluation of pharmacokinetics (PK), pharmacodynamics (PD), and alternative pathway inhibition biomarkers to determine a PK/PD relationship for ACH-5228.

“We aim to evolve our oral factor D portfolio to enable alternative pathway inhibition throughout a variety of rare diseases.”

The trial is expected to be concluded in the third quarter of this year.

Achillion Pharmaceuticals executive vice-president and chief medical officer Steven Zelenkofske said: “This important clinical milestone for our next-generation oral factor D inhibition program marks an exciting time at Achillion as we pursue safe, effective and innovative treatments for patients with complement-mediated diseases.

“With ACH-5228’s profile, we aim to evolve our oral factor D portfolio to enable alternative pathway inhibition throughout a variety of rare diseases.”

In a previous single ascending dose study, ACH-5228 showed improved potency and pharmacokinetic properties compared to Achillion’s first-generation factor D inhibitor ACH-4471.

This data is anticipated to provide additional inhibition of alternative pathway (AP) and to reduce the frequency of dosing for patients with immune-related diseases of AP of the complement system.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena